PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.22%
Negative net income growth while VET stands at 78.07%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
10.34%
Some D&A expansion while VET is negative at -0.46%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-173.24%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
74.47%
Well above VET's 68.46% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.47%
Growth well above VET's 68.46%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
123.72%
Some yoy increase while VET is negative at -81.34%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
12.92%
Some CFO growth while VET is negative at -4.80%. John Neff would note a short-term liquidity lead over the competitor.
-19.75%
Negative yoy CapEx while VET is 7.83%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.00%
We reduce yoy other investing while VET is 85.03%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-105.59%
We reduce yoy invests while VET stands at 35.72%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
32.90%
Debt repayment growth of 32.90% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
95.48%
We slightly raise equity while VET is negative at -52.58%. John Neff sees competitor possibly preserving share count or buying back shares.
12.03%
Buyback growth of 12.03% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.